Persistence of antibody to influenza A/H5N1 vaccine virus: Impact of AS03 adjuvant

Clinical and Vaccine Immunology

Volumn 23, Issue 1, 2016, Pages 73-77

  Chen, Wilbur H ^a   Jackson, Lisa A ^b   Edwards, Kathryn M ^c   Keitel, Wendy A ^d   Hill, Heather ^e   Noah, Diana L ^f   Creech, C Buddy ^c   Patel, Shital M ^d   Mangal, Brian ^e   Kotloff, Karen L ^a  

^a University of Maryland School of Medicine Center for Vaccine Development   (United States)

^b GROUP HEALTH RESEARCH INSTITUTE   (United States)

^c VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^d BAYLOR COLLEGE OF MEDICINE   (United States)

^e EMMES CORPORATION   (United States)

^f SOUTHERN RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AS03 ADJUVANT; IMMUNOLOGICAL ADJUVANT; INFLUENZA VACCINE; UNCLASSIFIED DRUG; VIRUS ANTIBODY; ALPHA TOCOPHEROL; ASO3B ADJUVANT; DRUG COMBINATION; POLYSORBATE; SQUALENE;

ADULT; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CONTROLLED STUDY; HUMAN; IMMUNOGENICITY; INFLUENZA A (H5N1); INFLUENZA A VIRUS (H5N1); INFLUENZA VACCINATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VIRUS STRAIN; ADOLESCENT; ADVERSE EFFECTS; BLOOD; CLINICAL TRIAL; DOUBLE BLIND PROCEDURE; DRUG COMBINATION; FEMALE; IMMUNOLOGY; INFLUENZA, HUMAN; MALE; MIDDLE AGED; MULTICENTER STUDY; TIME FACTOR; VACCINATION; YOUNG ADULT;

ADJUVANTS, IMMUNOLOGIC; ADOLESCENT; ADULT; ALPHA-TOCOPHEROL; ANTIBODIES, VIRAL; DOUBLE-BLIND METHOD; DRUG COMBINATIONS; FEMALE; HUMANS; INFLUENZA A VIRUS, H5N1 SUBTYPE; INFLUENZA VACCINES; INFLUENZA, HUMAN; MALE; MIDDLE AGED; POLYSORBATES; SQUALENE; TIME FACTORS; VACCINATION; YOUNG ADULT;

EID: 84954328201     PISSN: 15566811     EISSN: 1556679X     Source Type: Journal    
DOI: 10.1128/CVI.00475-15     Document Type: Article

References (11)

1. Jennings LC, Monto AS, Chan PK, Szucs TD, Nicholson KG. 2008. Stockpiling prepandemic influenza vaccines: a new cornerstone of pandemic preparedness plans. Lancet Infect Dis 8:650-658. http://dx.doi.org/10.1016/S1473-3099(08)70232-9.
2. Chen WH, Jackson LA, Edwards KM, Keitel WA, Hill H, Noah DL, Creech CB, Patel SM, Mangal B, Kotloff KL. 2014. Safety, reactogenicity, and immunogenicity of inactivated monovalent influenza A(H5N1) virus vaccine administered with or without AS03 adjuvant. Open Forum Infect Dis 1:ofu091. http://dx.doi.org/10.1093/ofid/ofu091.
3. Noah DL, Hill H, Hines D, White EL, Wolff MC. 2009. Qualification of the hemagglutination inhibition assay in support of pandemic influenza vaccine licensure. Clin Vaccine Immunol 16:558-566. http://dx.doi.org/10.1128/CVI.00368-08.
4. Rowe T, Abernathy RA, Hu-Primmer J, Thompson WW, Lu X, Lim W, Fukuda K, Cox NJ, Katz JM. 1999. Detection of antibody to avian influenza A (H5N1) virus in human serum by using a combination of serologic assays. J Clin Microbiol 37:937-943.
5. Langley JM, Frenette L, Ferguson L, Riff D, Sheldon E, Risi G, Johnson C, Li P, Kenney R, Innis B, Fries L. 2010. Safety and cross-reactive immunogenicity of candidate AS03-adjuvanted prepandemic H5N1 influenza vaccines: a randomized controlled phase 1/2 trial in adults. J Infect Dis 201:1644-1653. http://dx.doi.org/10.1086/652701.
6. Langley JM, Risi G, Caldwell M, Gilderman L, Berwald B, Fogarty C, Poling T, Riff D, Baron M, Frenette L, Sheldon E, Collins H, Shepard M, Dionne M, Brune D, Ferguson L, Vaughn D, Li P, Fries L. 2011. Dose-sparing H5N1 A/Indonesia/05/2005 pre-pandemic influenza vaccine in adults and elderly adults: a phase III, placebo-controlled, randomized study. J Infect Dis 203:1729-1738. http://dx.doi.org/10.1093/infdis/jir172.
7. Risi G, Frenette L, Langley JM, Li P, Riff D, Sheldon E, Vaughn DW, Fries L. 2011. Immunological priming induced by a two-dose series of H5N1 influenza antigen, administered alone or in combination with two different formulations of AS03 adjuvant in adults: results of a randomised single heterologous booster dose study at 15 months. Vaccine 29:6408-6418. http://dx.doi.org/10.1016/j.vaccine.2011.04.072.
8. Coudeville L, Bailleux F, Riche B, Megas F, Andre P, Ecochard R. 2010. Relationship between haemagglutination-inhibiting antibody titres and clinical protection against influenza: development and application of a Bayesian random-effects model.BMCMed Res Methodol 10:18. http://dx.doi.org/10.1186/1471-2288-10-18.
9. Hobson D, Curry RL, Beare AS, Ward-Gardner A. 1972. The role of serum haemagglutination-inhibiting antibody in protection against challenge infection with influenza A2 and B viruses. J Hyg (Lond) 70:767-777. http://dx.doi.org/10.1017/S0022172400022610.
10. Leroux-Roels I, Bernhard R, Gérard P, Dramé M, Hanon E, Leroux- Roels G. 2008. Broad clade 2 cross-reactive immunity induced by an adjuvanted clade 1 rH5N1 pandemic influenza vaccine. PLoS One 3:e1665. http://dx.doi.org/10.1371/journal.pone.0001665.
11. Leroux-Roels I, Roman F, Forgus S, Maes C, De Boever F, Dramé M, Gillard P, van der Most R, Van Mechelen M, Hanon E, Leroux-Roels G. 2010. Priming with AS03 A-adjuvanted H5N1 influenza vaccine improves the kinetics, magnitude and durability of the immune response after a heterologous booster vaccination: an open non-randomised extension of a double-blind randomised primary study. Vaccine 28:849-857. http://dx.doi.org/10.1016/j.vaccine.2009.10.017.